GlassScriptPhysician profile
Robert J Updaw
NPI 1215115332
$1,217.63
in general payments reported to CMS, 2019-2025
19 companies · $22.37 in 2025
The $22.37 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.00 · 2020: $13.46 · 2021: $176 · 2022: $634 · 2023: $287 · 2025: $22.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $231.00 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $186.80 | 2022-2023 | Nucala, Arexvy, Shingrix |
| Genzyme Corporation | $176.82 | 2021-2023 | |
| Mylan Specialty L.P. | $92.09 | 2019-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Merck Sharp & Dohme LLC | $58.25 | 2019-2022 | |
| Gilead Sciences, INC. | $55.25 | 2021-2022 | |
| Melinta Therapeutics, LLC | $48.67 | 2022 | |
| Pulmonx Corporation | $46.94 | 2019-2022 | |
| Grifols USA, LLC | $44.38 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.82 | 2022-2023 | Fasenra, Tezspire |
| Masimo Corporation | $28.86 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.37 | 2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $21.07 | 2023 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $20.35 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.52 | 2022 | |
| Baxter Healthcare | $18.09 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Nabriva Therapeutics, Plc | $14.77 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Updaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.